As of February 2026 | Revision C – Updated and verified Feb 17, 2026
20+ minute read. It’s a lot – but so is the decision you might be making.
Five years ago, if you had Usher syndrome or retinitis pigmentosa and asked about treatment, the answer was simple: there isn’t one. Luxturna existed for a tiny fraction of RP patients – RP being a genetic disease that slowly kills the light-sensing cells in your retina – those with RPE65 mutations, less than 5% of cases – and for everyone else, the conversation was short. Wear sunglasses. Take vitamin A. Wait.
That answer is no longer true. Well – the sunglasses part is still good advice for everyone.
Today, there are more than 50 therapies under active investigation for inherited retinal diseases alone. Gene therapy. Stem cells. CRISPR gene editing. Optogenetic proteins that turn surviving cells into substitute photoreceptors. An oral pill that slows vision loss – just a pill, twice a day, no surgery. Some of these are in Phase 3 trials (the final stage of testing before FDA approval – Phase 1 checks safety, Phase 2 checks if it works, Phase 3 proves it at scale). Some are filing for FDA approval right now.
I’m writing this from inside the Usher syndrome and retinitis pigmentosa world, because that’s what I live with. But the problem I’m about to describe isn’t unique to my condition. If you or someone you love is facing any disease with clinical trials and nobody to help you navigate them – this is your story too.
Whether you have Usher syndrome – Type 1, 2, or 3 – or non-syndromic retinitis pigmentosa, the same retina is degenerating, the same light-detecting cells in your retina (photoreceptors) are dying, and many of the same therapies could help. RP without hearing loss affects roughly 1 in 4,000 people – potentially millions worldwide. Usher syndrome affects over 400,000. Together, we are a large community facing the same set of questions.
The science has exploded. But something hasn’t kept up.
Nobody is helping patients think about what to do with all of this.
One important note: I dated this essay February 2026 for a reason. This landscape moves fast. A trial recruiting today could be full tomorrow. A therapy approaching FDA approval could fail next month. What I’ve written here is a snapshot – accurate as of when I researched it, but not permanent. If you’re reading this months or years later, verify everything. The questions I’m raising don’t expire, but the specific answers do.
The Menu Nobody Explains
Here’s what’s actually out there, simplified. Not a list of every trial – just the categories, so you understand what’s on the table.
Gene therapy delivers a working copy of your broken gene directly into the retina. If it works, one injection could be a permanent fix. But here’s the catch: the delivery vehicle – a tiny virus called AAV – can only carry a gene up to about 4.7 kilobases (units of DNA length) in size. Some genes fit. Some don’t. Your genetic diagnosis determines whether gene therapy is even possible for you today.
Exon skipping is the next approach – and to understand it, you need to know that a gene is made up of sections called exons (think of them as chapters in an instruction manual). If one chapter is damaged, exon-skipping therapy tells the cell to skip that chapter and read the rest, producing a shorter but partially functional protein. The medical name for these therapies is antisense oligonucleotides (ASOs). They require repeated injections. Right now, the only ASO in trials for USH2A targets exon 13 – one specific chapter. But new research is pushing further – researchers have demonstrated multi-exon skipping in zebrafish for different parts of the USH2A gene, which means the approach could eventually reach patients whose mutations are in other chapters.
Cas13 RNA editing is an emerging approach worth knowing about. Instead of cutting DNA like CRISPR, it edits the RNA message – the working copy your cell makes from the DNA blueprint – correcting errors without permanently altering your genome. Early lab work has shown promising efficiency for USH2A, but it’s still in the early stages.
Neuroprotection takes a completely different approach. Instead of fixing the gene, it protects the cells you still have. Your rods (the cells that handle night vision and peripheral vision) die first – that’s the genetic part. But your cones (the cells that handle central vision and color) die second, from oxidative stress – basically, they’re drowning in oxygen that the rods used to consume. A neuroprotective drug fights that oxidative damage. It doesn’t fix the cause, but it slows the collapse.
Optogenetics is the most radical idea. When your photoreceptors are gone – rods, cones, all of them – there are still other cells in the retina. Optogenetic therapy delivers a synthetic light-sensitive protein to those surviving cells, essentially turning them into substitute photoreceptors. This works even in advanced disease, when other therapies can’t help.
Cone reactivation is a new approach that sits between neuroprotection and optogenetics. Some cones in advanced RP aren’t dead – they’re dormant. They still have their light-sensing proteins but they’ve gone silent. This therapy delivers a gene that wakes them up. The first patient was treated in October 2025. If it works, it could offer better vision than optogenetics because the cells being reactivated are real cones, not repurposed cells. (Added Feb 17, 2026 – SparingVision NYRVANA trial)
Cell replacement is exactly what it sounds like. Lab-grown photoreceptors injected into the retina to replace the ones you’ve lost. This is the earliest-stage approach, but it’s real – the first patients were treated in 2025.
That’s the menu. Seven fundamentally different approaches, each with different trade-offs. And the first thing you should notice is that most of them don’t require knowing your gene at all.
Why Some People Have Options and Others Don’t
This is where it gets unfair.
If you have RP caused by RPGR mutations – the most common form of X-linked RP – your gene is about 3.5 kilobases (a measure of gene size – think of it like file size for DNA). It fits in one AAV (a harmless virus used as a delivery vehicle to carry the corrected gene into your cells) easily. Multiple gene therapy trials are running, including a Phase 2/3 trial with data expected later this year.
If you have Usher Type 1B, caused by mutations in MYO7A, your gene is about 6.6 kilobases – too big for a single AAV, but researchers figured out how to split it across two. Dual-AAV gene therapy. The trial (LUCE-1) has completed enrollment – 15 adults dosed – and they’re now collecting safety data. That’s real progress for a gene that was considered untreatable not long ago.
If you have RP caused by PDE6B mutations, there’s a gene therapy in trials with positive two-year data. CNGA1 mutations – a novel AAV approach is testing increasing doses. Even PRPF31, which causes a form of autosomal-dominant RP (meaning one broken copy of the gene is enough to cause it, unlike most RP which needs two), has an RNA therapy (a treatment that works at the instruction level of the gene, rather than replacing the whole gene) in Phase 2/3.
But if you have Usher Type 2A – the most common form, affecting roughly half of all Usher syndrome patients worldwide – your gene, USH2A, is 15.6 kilobases. That’s more than three times too big for AAV. It doesn’t fit in one vector. It doesn’t even fit in two. The standard delivery truck can’t carry it.
And USH2A isn’t alone. The EYS gene, responsible for another common form of RP, is about 9.5 kilobases – also too big, also with no gene therapy trials. If you lost the genetic lottery with a large gene, you’re in the same position.
Let that sink in. The most common form of Usher syndrome has the hardest gene to treat. And it’s not even close. I learned this about my own gene sitting at my desk one afternoon. Nobody had ever told me.
And it goes deeper than just the gene. Two people can both have USH2A and be on completely different paths. It depends on what’s actually broken. Think of it like two cars that won’t start. One has a bad spark plug – the part is there but it’s not firing right. That’s like having one letter changed in the DNA code (a missense mutation) – the gene is all there, it just has a typo. Therapies like base editing might be able to fix that typo directly. The other car has a cracked engine block – you’re not swapping parts, you need a different plan entirely. That’s like my situation. One of my USH2A mutations is a whole section deleted (exons 22-24 – gone, not there). You can’t edit what’s missing. Same gene. Different break. Different fix. That’s why “USH2A gene therapy” isn’t one conversation – it’s a dozen different conversations depending on what exactly went wrong in your copy.
But here’s something that works in our favor: not all mutations are equally rare. One specific USH2A mutation – c.2299del – accounts for 20 to 25 percent of all disease-causing USH2A variants. One in four or five. That means it’s the most studied, the most well-characterized, and the most likely to be targeted first when mutation-specific treatments arrive. If your genetic report shows that variant, you’re not alone in the dark – you’re in the largest group of USH2A patients there is. (Added Feb 17, 2026)
The only gene-specific option for USH2A right now is an ASO that skips exon 13 – and that only helps patients whose mutations happen to be in exon 13. But the science is moving. Researchers have proven multi-exon skipping works in zebrafish for exons 30-31 and 39-40, and Tim Yu – the researcher who created milasen, the first personalized ASO – is developing new USH2A ASOs through the PUSH initiative. The approach could eventually scale to cover different mutations across the gene. That’s not here yet, but it’s not theoretical either.
If your mutations are somewhere else in that massive gene, there is no gene-specific therapy in trials today. The CRISPR approach for USH2A – EDIT-102 – is dead. Editas quit retinal disease entirely in January 2023, cut 20% of staff, and pivoted to other conditions. The program is still orphaned – no partner has picked it up, no IND has been filed, and there is no clinical timeline. I’m not sugarcoating that. It’s a real setback. (Verified Feb 17, 2026 – confirmed still dead)
This is why gene-independent therapies matter so much. The neuroprotective pill doesn’t care what gene you have. Optogenetics doesn’t care. Cell replacement doesn’t care. For USH2A patients, EYS patients, and anyone else with a gene that doesn’t fit in an AAV vector, these gene-agnostic approaches aren’t a fallback plan. They’re the primary hope.
The Real Risks Nobody Talks About
Before I talk about risk, I want to be clear: real progress is happening. An oral neuroprotective pill showed over 50% reduction in photoreceptor loss in a two-year trial – though the primary endpoint didn’t reach statistical significance, the trend was strong enough for the FDA to grant it Breakthrough Therapy status. (Updated Feb 17, 2026 – Nacuity Phase 1/2 results) Optogenetic therapy has shown sustained vision gains after a single injection. Three therapies are approaching FDA approval right now. This is not false hope – this is science delivering results.
But hope without information is dangerous. And there are three layers of risk that nobody is explaining clearly.
The first risk is physical. Trials can make you worse. This isn’t theoretical. In a recent gene therapy trial for PDE6A mutations, two out of nine patients experienced severe vision loss. A major Phase 3 gene therapy trial for RPGR – backed by Johnson & Johnson – failed its primary endpoint in May 2025. These are not rare complications buried in fine print. These are real outcomes that happened to real people who volunteered for science.
Trials are not “free treatment.” They are experiments. The earlier the phase, the less is known about safety. You are helping researchers learn – and that is valuable – but you need to understand what you’re risking.
The second risk is strategic. When you receive an AAV-based gene therapy – an injection into your eye – your immune system produces defense fighters called antibodies against that viral vector. Those antibodies can reduce the effectiveness of a second gene therapy. You may have just used your one shot, and it might affect your eligibility for something better that comes along in three years.
Nobody explains this to patients in strategic terms. In clinical trial language, being untreated is called “treatment-naive.” The word makes it sound like you don’t know any better. The reality is nobody offered you anything.
But that status is actually a strategic advantage. If you take a pill first – a pill that shields your remaining light-sensing cells from dying (a neuroprotectant), requires no surgery, and, based on what we know today, doesn’t create the antibodies that could complicate future gene therapy – you’ve likely preserved your future options. Gene therapy can still come later. The pill is unlikely to close doors that an injection might.
An important reality check: As of early 2026, that neuroprotective pill is not something you can walk into a doctor’s office and get. NPI-001 completed Phase 1/2 and has a confirmatory trial planned, but it hasn’t started yet. The NAC Attack trial at Johns Hopkins is enrolling – 485 patients across 31 sites – but it’s still a trial, not a prescription. Over-the-counter N-acetylcysteine supplements exist, but they’re not the same clinical-grade formulation and nobody knows if they work the same way. The strategy is sound. The access isn’t there yet. I’m in the same position you are – I can see the logic, and I can’t get the pill either.
This isn’t obscure science. The AAV antibody problem is well-documented in medical journals. The strategic implication – that treatment ORDER matters, that a pill before an injection might be the smarter sequence – is obvious once you see it. But nobody is telling patients.
The third risk is timing. You’re always losing. The question is whether what you have left right now is enough to wait for something better, or whether the clock is forcing your hand.
If you still have central vision worth protecting – and vision loss is a spectrum, so only you know where you are on it – jumping into an early-phase gene therapy could mean risking what you have AND generating antibodies that block the next therapy. Based on what we know today, that’s a double hit that may be very difficult to undo.
But if your vision is advanced-stage – very narrow field, struggling daily – the calculus shifts. You have less to risk and less time to wait. Earlier-phase trials may make more sense. Optogenetics was designed specifically for people who have already lost most of their photoreceptors.
Where you are in the progression changes everything. And nobody is helping you figure out where that line is for YOUR situation.
And if you’re a parent making this decision for a child, it’s even harder. A mother recently told me she’s been dragging her 17-year-old son to professors all over Poland – each one says something different, and the last one told her flat out there’s nothing. Another parent pointed out that acting too early with one therapy could trigger an immune response that limits what you can do later – but waiting too long means losing the cells a better therapy would need. Parents are being asked to sequence treatments for their kids with no framework and no guidance. That’s not a gap. That’s a cliff.
But What About Placebo?
One question that comes up a lot – and it’s a fair one – is: what if I join a trial and just get the placebo?
Here’s what happens in most cases. At the end of the trial, they “unblind” – they tell you which group you were in. If you got the placebo and the therapy worked, most trials offer what’s called an open-label extension, which means the placebo group gets access to the real treatment. You’re not abandoned.
And increasingly, newer eye trials avoid the placebo problem entirely. They treat one eye and use your other eye as the control. No placebo. No guessing.
A few other things worth knowing: being in one trial doesn’t block you from joining another later (though you may need a washout period between them). And regardless of which arm you’re in – treatment, placebo, even if the trial fails – the Foundation Fighting Blindness considers trial participants “pioneers.” You contributed to the science. That data matters whether the therapy worked for you personally or not.
The placebo fear is understandable. But it shouldn’t be the thing that keeps you from considering a trial.
The Clock
While you’re weighing these decisions, your retina isn’t waiting.
Retinitis pigmentosa is measurable. A layer on your retinal scan that shows where you still have intact light-sensing cells – doctors call it the ellipsoid zone – shrinks over time. How fast depends on your gene, your mutations, your age – one large study of USH2A patients measured it at roughly 107 micrometers per year (about the width of a single human hair – lost every year), but the rate varies widely across different types of RP. What doesn’t vary is the direction. Every year, the ring of surviving photoreceptors gets smaller. Every year, there are fewer cells left to save.
You’re always losing. It never stops. It never stabilizes. I think about this every time I notice something I could see last year that I can’t see now.
Most gene therapies and neuroprotective treatments require that you still have photoreceptors to rescue. If you wait too long, you pass a point where the cells are gone and those therapies have nothing to save. Animal studies suggest that treating too late significantly reduces or eliminates the benefit.
The exceptions – optogenetics and cell replacement – are designed to work even after photoreceptors are gone. Early results suggest they don’t need your original cells to provide benefit. That’s why they matter so much for people further along in the progression.
But here’s the tension nobody talks about honestly: waiting for a better therapy might mean losing the cells that therapy needs to work. Acting now might mean closing the door on something more effective coming in two years. Every patient lives in this tension, and the right answer is different for everyone. There are no fixed rules. No two patients progress the same way. You’ll make this decision without complete information – and nobody can tell you if you got it right. That uncertainty is one of the hardest parts of living with this.
The Doctor Problem
Here’s what makes all of this worse: most patients can’t get help navigating it even if they want to.
I don’t know which doctor I’m supposed to see for this. A retinal specialist? Mine told me “there’s nothing out there” – which was factually wrong. A genetic counselor? They interpret your mutations but don’t track the treatment landscape. A low-vision specialist? They help you cope with what you have, not plan for what’s coming. Your primary care doctor? They’ve probably never heard of Usher syndrome. I’m still not sure which one I’m supposed to call.
After months of building context with AI tools, I found four active clinical trials I likely qualify for – trials no doctor had ever mentioned. Not through a genetic counselor. Not through a patient organization. I used an AI assistant – and I need to be very clear about what that means.
Through that work, I learned more about my treatment options than I had in fourteen years since my diagnosis. I described my genetic mutations, my visual field, my acuity, and asked: what’s out there for me?
This isn’t a criticism of doctors. It’s a structural problem. Doctors have limited time, and their patients have hundreds of conditions. They focus on the ones they see most – which makes sense for them but fails anyone with something rare. The rarer your condition, the wider the gap. And Usher syndrome, at 1 in 10,000 to 1 in 25,000, is very rare. Your retinal specialist might see one or two USH patients a year. They can’t track the trial landscape for every rare condition they encounter. “Nothing’s out there” isn’t malice – it’s the default answer that takes zero research time for a condition that represents a fraction of their practice. And even if they wanted to dig deeper – there’s no billing code for it. Insurance pays doctors for visits and procedures, not for spending a hundred hours researching one patient’s rare condition. The system doesn’t allow it. That’s why I learned to do it myself – and why I’m writing this essay, so you at least know what questions to bring to the conversation.
And it gets worse. Even if a doctor wanted to help you navigate the treatment landscape, they don’t have the tools. There is no system in any hospital or clinic that takes a patient’s genetic profile, cross-references it against active trials, weighs the strategic implications of treatment order, and produces a personalized roadmap. That tool doesn’t exist. Not in the biggest research hospitals. Not in the most funded medical centers. With all the money in the healthcare system, nobody has built it.
The result is that patients like me are on their own. I’m doing what a specialist should be doing for me – reading trial databases, understanding eligibility criteria, thinking about which therapy to pursue, and in what order. I’m doing it because nobody else will. And the system that tells me “don’t self-diagnose” is the same system that offers me nothing in return.
And I have an engineering background, decades of technical experience, and access to AI tools. What about the patient who doesn’t?
A Word About AI (Read This Carefully)
I want to be direct about the AI part, because I don’t want anyone to read this essay and do something dangerous.
When I say I used AI to research my treatment options, I am not saying I opened a free chatbot and asked “what clinical trial should I join?” That would be reckless, and the results would be unreliable.
Here’s what I actually did:
I use a paid, top-tier AI model – not a free chatbot. I pay for the most capable plan available because the quality of the reasoning matters when you’re dealing with medical decisions. I fed it my full genetic test report, my audiogram, my medical history, my visual field measurements. I built context over hundreds of hours of conversation – not one quick question.
And critically: I verified everything. AI gets things wrong. It can hallucinate trial names, invent eligibility criteria, confuse one therapy with another. I caught errors and corrected them. I cross-checked every claim against ClinicalTrials.gov, published research, and organization websites. When the AI said something I couldn’t verify, I threw it out.
This is a skill, not a shortcut. I have 39 years of engineering experience that taught me how to evaluate technical information critically. Even with all of that, what I find may not be 100% right. The treatment landscape changes weekly. A trial that was enrolling yesterday may have stopped today.
Please do not read this essay and go ask a free AI chatbot what trial you should join. The information you get may be outdated, incorrect, or completely fabricated. On top of that, most AI models – free or paid – only know what existed when they were trained, and that data is typically six months to a year old. In a landscape where trials open and close every week, the AI might confidently tell you about a trial that’s already full, failed, or never existed. AI is a powerful research tool – but only if you bring deep context, verify everything, and understand its limitations.
What I found through months of careful research was more than my doctors had told me in fourteen years. That’s real. But I didn’t find it by typing a question into a chat box. I found it by doing the hard work that someone in the medical system should be doing for patients like us.
The Hearing Side (A Stark Contrast)
I have Usher syndrome, which means I’m losing both vision and hearing. Everything I’ve written above is about the vision side – and the vision side has over 50 active trials. Three therapies are approaching FDA approval right now.
The hearing side? As of February 2026, there are exactly four legitimate clinical trials for genetic hearing loss. All four target a single gene – OTOF – which causes auditory neuropathy, not Usher syndrome. For Usher syndrome hearing loss – any type, not just mine – there are zero trials. Not one. Not even preclinical. And the OTOF trials can’t help us – they fix a signaling problem in otherwise healthy hair cells. Usher syndrome damages the hair cells themselves. It’s a different problem entirely. I’ve had hearing loss since birth. Fifty trials for my eyes. Zero for my ears. And for those with Usher Type 1 who also deal with balance problems – there’s nothing on that front either. No trials, no drugs, no gene therapy. But here’s the thing – physical therapy actually helps. Balance training and vestibular rehab can make a real difference for people with Type 1, especially kids. The problem is the same one we keep running into: nobody tells parents it exists. One Coalition ambassador with Type 1 told me she wishes her childhood doctor had listened when her mom asked about PT. By the time she found it on her own, she’d already spent years struggling with something that could have been managed. The tools exist. The referrals don’t. I’m not sure what to do with any of that.
The USH2A gene is too big for AAV delivery to the ear, just like it’s too big for the eye. But while vision researchers have found creative workarounds – gene-agnostic approaches, neuroprotection, optogenetics – nobody has done the same for hearing. The cochlear damage in Usher syndrome happens during development, and by adulthood, it may be structural damage that gene therapy can’t reverse.
There is one small sign of progress. In 2025, Save Sight Now achieved the first hearing rescue in a MYO7A mouse model – proving that gene therapy can reach beyond vision to hearing, at least in the lab. It’s a mouse, not a human, and it’s one gene, not all of Usher. But it’s the first time anyone has demonstrated hearing rescue in an Usher model. That matters.
Meanwhile, the hearing treatment space is flooded with false hope. Hair cell regeneration therapies that showed zero benefit in Phase 2 trials. Companies that raised millions and then dissolved. Stem cell clinics charging 5,000𝑡𝑜30,000 for unproven treatments. Supplements marketed as hearing restoration with no clinical evidence.
For now, hearing aids and eventually cochlear implants remain the only proven interventions for Usher syndrome hearing loss. I mention this not to be discouraging, but because honesty matters more than hope. The vision landscape is genuinely exciting. The hearing landscape is not there yet. Knowing the difference protects you from spending money and hope on things that don’t work.
What Should Exist
Two things are missing that should be straightforward to build.
A framework for thinking about your options. Not medical advice. Not “do this.” A set of questions: Given your gene, your specific mutation, where you are in the progression, your age, and what’s available – here’s what to ask your doctor. Here’s what to look up before you enroll in anything.
Someone in the medical system who thinks about this from the patient’s side. Right now, researchers think about their trial. Doctors think about their specialty. Organizations think about enrollment. Nobody is thinking about the patient sitting in the middle of it all, trying to figure out which door to walk through when every door might close others behind it.
Why I Wrote This
I’m not a doctor. I’m an engineer with Usher syndrome who built his own research tools because nobody else would do this work for him. That fact alone tells you something is broken.
This essay is the beginning of filling that gap. Not with answers – with the right questions. Because once you know what to ask, you can start finding your own answers. And if your doctor can’t help you navigate it, at least now you know what to navigate.
I wrote this about Usher syndrome and RP because that’s what I live with. But this gap exists across every disease where clinical trials are the path to treatment. If you’re facing it in your world, the same questions apply. Which trial first? What am I giving up? Who’s helping me decide?
Five years ago, there was nothing. Today, there are over 50 trials and three therapies approaching approval. The gap is real – but so is the progress. We are closer than we have ever been. No one should have to navigate this alone.
Where Things Stand: February 2026
The treatment landscape changes fast. Below is a snapshot of what’s active or approaching approval as of this writing. Verify current status before making any decisions.
Approaching FDA Approval
Therapy Company Type For Whom Status MCO-010 Nanoscope Optogenetic Advanced RP, any gene Rolling BLA, 3-year durability data OCU-400 Ocugen Gene-agnostic gene therapy Any RP BLA submission H1 2026 + Expanded Access granted (Updated)DB-OTO Regeneron Hearing gene therapy OTOF hearing loss only (not USH) NEJM published: 11/12 improved, 3 normal hearing
Phase 3 / Late-Stage Trials
Therapy Company Type For Whom Status NPI-001 (NACA) Nacuity Oral pill (neuroprotection) All USH/RP Breakthrough Therapy; Phase 3 planned 2026 (Updated)NAC Attack Johns Hopkins/NEI Oral pill (neuroprotection) All RP 485 patients, 31 sites – largest RP trial ever (Updated)Laru-zova Beacon Gene therapy RPGR/X-linked RP Phase 2/3 fully enrolled, positive 9-month interim (Updated)
Phase 1-2 Trials (Selected)
Therapy Company Type For Whom Status AAVB-081 (LUCE-1) AAVantgarde Dual-AAV gene therapy USH1B (MYO7A) Enrollment complete, 15 adults Ultevursen (LUNA) Sepul Bio ASO exon skipping USH2A exon 13 only (~16,000 patients worldwide) Phase 2b, 81 patients enrolling (Updated)SPVN06 SparingVision Cone preservation All RP (gene-agnostic) Dosing COMPLETE Feb 2026; pivotal trial 2027 (Updated)SPVN20 (NYRVANA) SparingVision Cone reactivationAdvanced RP (gene-agnostic) NEW – first patient Oct 2025 (Added)jCell jCyte Retinal progenitor cells All RP (gene-agnostic) Phase 2b, Q1 2026 interim results expected OpCT-001 BlueRock/Bayer iPSC cell replacement Advanced RP Fast Track + Orphan Drug (Jan 2026)(Updated)HORA-PDE6b eyeDNA Gene therapy PDE6B mutations Positive 24-month data; seeking accelerated path (Updated)BF844 Usher III Initiative Small molecule (oral) USH Type 3 (CLRN1) Phase 1 complete, bridge to Phase 2 ZVS203e ZVS Bio CRISPR gene editing RHO mutations (first CRISPR for RP) Phase 1 dosing ZM-02 Zhongmou Optogenetic Advanced RP, any gene 52-week data: color perception recovered; US IND cleared (Updated)KIO-301 Kiora Molecular photoswitch Advanced RP, any gene Phase 2 ABACUS-2 enrolling; $400M+ partnership (Updated)
The Big Picture
Category Active Trials Closest to Patients Gene-specific vision 22+ Laru-zova (RPGR), ultevursen (USH2A exon 13) Gene-independent vision 18+ MCO-010, OCU-400, NPI-001, SPVN06, SPVN20 Hearing (all genes) 4 DB-OTO (OTOF only) Hearing for USH 0 Nothing
Questions From the Community
This essay generated something I didn’t expect. Within days of posting it, questions started coming in – from the USH Blue Book, Facebook, LinkedIn, and private emails. A lot. From the US, Poland, Russia, Czech Republic, France, Italy, UK, Canada, Australia. All asking the same kinds of questions. All saying the same thing: nobody ever explained this to me.
That’s the guidance gap in real time. Here are some of the questions that came up most, with short answers based on what I’ve found. These are not medical advice – they’re one patient’s research. Verify everything with your own doctors and at ClinicalTrials.gov.
“What’s out there for USH2A specifically?”
Leo M. (London, UK) – brother has USH2A | Dan C. – daughter, 23, USH2A | Marzena G. (Poland) – son, 17, USH2A
The honest answer: less than we’d like. The USH2A gene is 15.6 kilobases – more than three times too big for standard gene therapy delivery. The only gene-specific option in trials right now is an ASO (exon-skipping therapy) that targets exon 13 – and that only helps if your mutation is in exon 13. But the gene-independent therapies – the neuroprotective pill, optogenetics, cone preservation, cell replacement – don’t care what gene you have. Those are the primary hope for USH2A right now. And the science is moving: multi-exon skipping has been demonstrated in the lab, and new ASOs are being developed through the PUSH Initiative.
“What if I join a trial and just get the placebo?”
Peter D. (Facebook)
Fair question. At the end of the trial, they unblind – they tell you which group you were in. If you got the placebo and the therapy worked, most trials offer what’s called an open-label extension: the placebo group gets access to the real treatment. You’re not abandoned. And increasingly, newer eye trials avoid the placebo problem entirely – they treat one eye and use your other eye as the control. No placebo. No guessing. Being in one trial also doesn’t block you from joining another later.
“The decision isn’t just gene-level – it’s mutation-level.”
Anna R. (Czech Republic) – son has USH1D
She’s right, and her point made the essay better. Two people with the same gene can be on completely different paths depending on what’s actually broken. A missense mutation (one letter changed) might be fixable with base editing. A deletion (a whole section missing) needs a different plan entirely. The type of break determines which therapies even apply. That’s why genetic testing isn’t optional – it’s the first step. And why “gene therapy for USH2A” isn’t one conversation. It’s a dozen different conversations.
“Has anyone heard of DMSO for RP?”
Adriana H. (Blue Book) – son, 21, USH2A
The only real study I found was 123 patients over 7 years in the 1980s. It showed no benefit. No eye doctors recommend it. This is exactly why I wrote this essay – there’s so much junk floating around out there, and when nobody’s explaining what’s real, people reach for whatever they can find. The treatments in the pipeline are real science with real data. DMSO is not one of them.
“Can photoreceptors recover after surgery?”
Tanya N. (Russia) – USH2A
In a healthy eye, some recovery is possible after surgery because the cells were stressed, not dead. In an Usher or RP eye, the photoreceptors are already dying from the gene. Surgery can help with swelling or other complications, but it can’t grow new cells. The decline is the disease. Her doctor should have explained the difference – and didn’t. That pattern came up over and over in the questions I received.
“Can RP/USH be non-inherited? Did it start with me?”
Brian V. (Blue Book) – USH2A
Almost certainly inherited – and this isn’t just USH2A. Almost every gene that causes RP or Usher syndrome follows the same pattern: autosomal recessive. You need two broken copies, one from each parent. Spontaneous (de novo) mutations are extremely rare across all of them. The math is the same for every recessive gene: carriers – people with one broken copy – have no symptoms and no idea they’re carrying it. For USH2A alone, that’s roughly 1 in 70 to 150 people. Two carriers meet, and each child has a 25% chance. These genes are ancient – versions of them exist in fish, frogs, and every vertebrate with a spine. The mutations have been quietly passed through human families for thousands of years. It didn’t start with you. You’re just the one who got two copies.
“Can my son wear contact lenses? His doctor says no.”
Marzena G. (Poland) – son Kacper, 17, USH2A, “large astigmatism”
Contacts are safe for RP. The retina issue has nothing to do with what sits on your cornea. But “large astigmatism” at 17 is a red flag for something else: keratoconus – a condition where the cornea thins and bulges. Peak onset is around age 15. Research shows 9-17% of teens diagnosed with “astigmatism” actually have early keratoconus that nobody checked for. The fix is a corneal topography scan – takes five minutes. If it’s KC, rigid gas permeable lenses or scleral lenses can correct it. If it’s not, regular contacts are fine. Either way, the answer isn’t “no contacts.” The answer is “check the cornea first.”
“Why does the haze in my vision get worse when I wear my reading glasses?”
Brian V. (Blue Book) – USH2A
This might be another keratoconus sign. Glasses sit about 12mm from your eye, and at that distance they amplify any irregularity in the cornea. If the cornea is warped even slightly, glasses make it worse. Hard contact lenses sit directly on the eye and bypass the corneal surface entirely – that’s why some people see better with contacts than glasses. If the haze is worse with glasses, get a corneal topography scan.
“Do the different USH types map to the different RP types?”
Christine N. (Canada) – recessive RP + undefined hearing loss
No. All three Usher types (1, 2, 3) are autosomal recessive – you need two broken copies. The old RP classification (dominant, recessive, X-linked) applies to non-syndromic RP. Some genes, like USH2A, can cause either Usher syndrome or RP alone, depending on which mutations you have. A genetic test could connect your RP and hearing loss – and might open doors to trials you don’t know about.
“Should we act now or wait for something better?”
Multiple parents – Marzena G. (Poland), Anna R. (Czech Republic), Victoria L. (New York)
This is the hardest question in the essay and nobody can give you a universal answer. The tension: waiting for a better therapy might mean losing the cells that therapy needs. Acting now might close the door on something more effective coming later. Where your child is in the progression changes everything. What I can say based on my research: a neuroprotective pill that preserves cells without surgery and without triggering immune responses that could block future gene therapy – based on what we know today, that’s likely the lowest-risk first step. It buys time without closing doors. But every case is different. That’s why the framework I describe in this essay matters more than any specific answer.
The Pattern
These questions came from ten countries. Parents, patients, researchers. All asking variations of the same thing: what’s out there, and why didn’t anyone tell me?
That’s the gap this essay is about. Not one country. Not one healthcare system. Everywhere.
What Changed in This Revision
This essay is a living document. Below is what was updated, added, or corrected in Revision C, with sources.
Date Change Source Feb 17, 2026 NPI-001: Added that primary endpoint did not reach statistical significance; >50% photoreceptor preservation was secondary measure Nacuity Phase 1/2 results, Sep 2025 Feb 17, 2026 NAC Attack: Updated to 485 patients across 31 sites (was ~438/30) Johns Hopkins / NEI protocol, Nov 2025 Feb 17, 2026 OCU-400: FDA granted Expanded Access Program (pre-approval access) Ocugen press release, 2025 Feb 17, 2026 SPVN06 (SparingVision): Dosing COMPLETE in PRODYGY trial; pivotal trial planned 2027 SparingVision press release, Feb 9, 2026 Feb 17, 2026 SPVN20/NYRVANA: NEW entry – cone reactivation therapy, first patient Oct 2025 SparingVision / FFB, Oct 2025 Feb 17, 2026 Cone reactivation added to treatment menu (now 7 approaches, was 6) SparingVision NYRVANA trial Feb 17, 2026 OpCT-001: Orphan Drug Designation added (Jan 22, 2026) Bayer/BlueRock press release Feb 17, 2026 ZM-02: 52-week data showing color perception recovery; FDA IND cleared for US Zhongmou Therapeutics, ARVO/eyewire Feb 17, 2026 KIO-301: Phase 2 ABACUS-2 enrolling; $400M+ Senju partnership Kiora Q3 2025 report Feb 17, 2026 HORA-PDE6b: Company renamed from Coave to eyeDNA; therapy renamed eyeDNA Therapeutics Feb 17, 2026 Ultevursen: Added 16,000 exon 13 patient estimate Sepul Bio / FFB Feb 17, 2026 EDIT-102: Confirmed still dead – no partner, no IND, no timeline Editas pipeline review Feb 17, 2026 Laru-zova: Fully enrolled, positive 9-month interim data from DAWN trial Beacon Therapeutics, EURETINA 2025 Feb 17, 2026 DB-OTO: NEJM published – 11/12 improved, 3 achieved normal hearing NEJM, 2025 Feb 17, 2026 Community Q&A section added – 10 questions from 10 countries USH Blue Book, Facebook, LinkedIn Feb 17, 2026 Gene-independent trial count updated to 18+ (was 15+) FFB pipeline, verified Feb 17, 2026 RUSH2A 4-year data now publicly available FFB / Jaeb Center, Nov 2025
All data verified against ClinicalTrials.gov, FFB pipeline, company press releases, and published research as of February 17, 2026.
This revision was shaped by conversations on the USH Blue Book, Facebook, and LinkedIn. Their questions made it better.
Mark Hubers has Usher syndrome Type 2A and has been losing his vision progressively since his twenties. He was diagnosed at 43 and is now 57. He writes about the experience of living with dual sensory loss – and increasingly, about the gap between what science promises and what patients actually receive.
Important: This essay reflects one patient’s research as of February 2026. It is not medical advice. The treatment landscape changes rapidly – trials open, close, succeed, and fail. Verify all information at ClinicalTrials.gov and with your healthcare providers before making any treatment decisions. Links to key resources:
ClinicalTrials.gov:
--> LINK: https://clinicaltrials.gov
Foundation Fighting Blindness Clinical Trial Pipeline:
--> LINK: https://www.fightingblindness.org/clinical-trial-pipeline
USH Coalition Clinical Trials:
--> LINK: https://www.usher-syndrome.org/research/clinical-trials.html
My Retina Tracker (free genetic registry):
--> LINK: https://www.myretinatracker.org
RUSH2A Natural History Data (4-year USH2A dataset, public access):
--> LINK: https://public.jaeb.org/ffb/view/RUSH2A